Une candidature complète en une minute
Un CV et une lettre de motivation personnalisés, prêts à envoyer.
Quotient Therapeutics seeks a Senior Director of Business Development to lead partnerships, asset licensing, and market intelligence. You will shape the portfolio, identify external opportunities, and execute strategic collaborations with senior leadership collaboration across R&D, clinical, regulatory, and finance teams.
You will drive end-to-end due diligence, negotiations, and deal structuring while advancing the company’s early-stage portfolio in a fast-paced environment.
Quotient is seeking an entrepreneurial, highly strategic Senior Director of Business Development to lead the company's partnering, asset in-licensing, and market intelligence activities. Reporting to the CFO, this individual will play a critical role in shaping the company's portfolio and business strategy, identifying external opportunities, and executing partnerships that create significant value for the company and its stakeholders.
The ideal candidate combines strong scientific and commercial judgment with demonstrated transaction leadership and the ability to operate effectively in an early-stage, fast-paced, resource-constrained environment. This person will be equally comfortable evaluating an external asset, developing a market landscape, engaging with potential partners, and working cross-functionally with R&D, clinical, regulatory, and executive leadership.
We are looking for someone with a proven track record in Business Development within the biotech or pharmaceutical sectors with significant experience leading collaboration and in-licensing deals and demonstrated strategic thinking and relationship building experience. On a personal level, Quotients enjoy a fast-paced environment, think like entrepreneurs, are adaptable, accountable, work proactively and look out for each other.
Essential
Quotient Therapeutics is a privately-held, early stage company developing breakthrough medicines informed by natural somatic genetic diversity present in patients. Through our work in somatic genomics, we are forging a new status quo for biopharma research and development across a broad pipeline of internal and partnered programs.
The company was founded by Flagship Pioneering, an innovative enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA), Generate Biomedicines, Sana Biotechnology (SANA), Tessera Therapeutics, Evelo Biosciences (EVLO), Indigo Agriculture, Seres Therapeutics (MCRB), and Syros Pharmaceuticals (SYRS).
Quotient Therapeutics and Flagship Pioneering are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.